Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation: A Multicenter, Randomized Phase II Clinical Trial

NCT07754734 is registered in ClinicalTrials.gov with Dongguan People's Hospital as lead sponsor.

NCT NCT07754734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07754734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation: A Multicenter, Randomized Phase II Clinical Trial
Lead sponsor
Dongguan People's Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 10, 2026
Completion date
July 31, 2029
Enrollment
138 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm), glioma, mgmt-methylated glioblastoma